Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/C4CA63D0.svg?ark=w1%2F20260526%2FC4CA63D0)](https://nobleid.org/work/w1/20260526/C4CA63D0)

ARK Inflections

Authors & Claims

Paper Authors